# Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5

> **NCT00722384** · PHASE1 · COMPLETED · sponsor: **OPKO Health, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** bevasiranib
- **DRUG:** bevasiranib

## Key facts

- **NCT ID:** NCT00722384
- **Lead sponsor:** OPKO Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2007-08
- **Final completion:** 2007-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2008-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00722384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00722384, "Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00722384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*